Functional Expression of Parasite Drug Targets and Their Human Orthologs in Yeast

Background The exacting nutritional requirements and complicated life cycles of parasites mean that they are not always amenable to high-throughput drug screening using automated procedures. Therefore, we have engineered the yeast Saccharomyces cerevisiae to act as a surrogate for expressing anti-parasitic targets from a range of biomedically important pathogens, to facilitate the rapid identification of new therapeutic agents. Methodology/Principal Findings Using pyrimethamine/dihydrofolate reductase (DHFR) as a model parasite drug/drug target system, we explore the potential of engineered yeast strains (expressing DHFR enzymes from Plasmodium falciparum, P. vivax, Homo sapiens, Schistosoma mansoni, Leishmania major, Trypanosoma brucei and T. cruzi) to exhibit appropriate differential sensitivity to pyrimethamine. Here, we demonstrate that yeast strains (lacking the major drug efflux pump, Pdr5p) expressing yeast (ScDFR1), human (HsDHFR), Schistosoma (SmDHFR), and Trypanosoma (TbDHFR and TcDHFR) DHFRs are insensitive to pyrimethamine treatment, whereas yeast strains producing Plasmodium (PfDHFR and PvDHFR) DHFRs are hypersensitive. Reassuringly, yeast strains expressing field-verified, drug-resistant mutants of P. falciparum DHFR (Pfdhfr 51I,59R,108N) are completely insensitive to pyrimethamine, further validating our approach to drug screening. We further show the versatility of the approach by replacing yeast essential genes with other potential drug targets, namely phosphoglycerate kinases (PGKs) and N-myristoyl transferases (NMTs). Conclusions/Significance We have generated a number of yeast strains that can be successfully harnessed for the rapid and selective identification of urgently needed anti-parasitic agents.

[1]  Túlio Marcos Santos,et al.  Characterization and comparative functional analysis in yeast of a Schistosoma mansoni Rho1 GTPase gene. , 2002, Molecular and biochemical parasitology.

[2]  S. Avery,et al.  The Antimalarial Drug Quinine Disrupts Tat2p-mediated Tryptophan Transport and Causes Tryptophan Starvation* , 2009, Journal of Biological Chemistry.

[3]  J. Ballesta,et al.  Functional complementation of yeast ribosomal P0 protein with Plasmodium falciparum P0. , 2005, Gene.

[4]  J. Bertino,et al.  Cancer research: from folate antagonism to molecular targets. , 2009, Best practice & research. Clinical haematology.

[5]  Yu Wang,et al.  Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. , 2011, Molecular and biochemical parasitology.

[6]  C. Sibley,et al.  Plasmodium falciparum: a novel method for analyzing haplotypes in mixed infections. , 2007, Experimental parasitology.

[7]  R. Schwarz,et al.  The Trypanosoma brucei sphingolipid synthase, an essential enzyme and drug target. , 2009, Molecular and biochemical parasitology.

[8]  P. Philippsen,et al.  Heterologous HIS3 Marker and GFP Reporter Modules for PCR‐Targeting in Saccharomyces cerevisiae , 1997, Yeast.

[9]  G. Santangelo,et al.  Heterologous Expression Studies of Saccharomyces cerevisiae Reveal Two Distinct Trypanosomatid CaaX Protease Activities and Identify Their Potential Targets , 2009, Eukaryotic Cell.

[10]  Wei Li,et al.  Yeast Model Uncovers Dual Roles of Mitochondria in the Action of Artemisinin , 2005, PLoS genetics.

[11]  G. Lefèvre,et al.  Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria , 2011, Annals of the New York Academy of Sciences.

[12]  Marcel Tanner,et al.  Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. , 2006, The Lancet. Infectious diseases.

[13]  T. Geary,et al.  Cloning of a cDNA encoding phosphoenolpyruvate carboxykinase from Haemonchus contortus. , 1992, Molecular and biochemical parasitology.

[14]  C. Sibley,et al.  Yeast as a model system to study drugs effective against apicomplexan proteins. , 1997, Methods.

[15]  K. Hoffmann,et al.  Development and Validation of a Quantitative, High-Throughput, Fluorescent-Based Bioassay to Detect Schistosoma Viability , 2010, PLoS neglected tropical diseases.

[16]  J. E. Hyde,et al.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.

[17]  C. Sibley,et al.  Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. , 2007, The American journal of tropical medicine and hygiene.

[18]  Ronald D. Klein,et al.  Recombinant Microorganisms as Tools for High Throughput Screening for Nonantibiotic Compounds , 1997 .

[19]  T. Geary,et al.  Cloning of a cDNA encoding phosphofructokinase from Haemonchus contortus. , 1991, Molecular and biochemical parasitology.

[20]  M. Zucca,et al.  Current Developments in the Therapy of Protozoan Infections , 2011, The open medicinal chemistry journal.

[21]  H. Westerhoff,et al.  A probabilistic approach to identify putative drug targets in biochemical networks , 2011, Journal of The Royal Society Interface.

[22]  Suman Gupta,et al.  Visceral leishmaniasis: Experimental models for drug discovery , 2011, The Indian journal of medical research.

[23]  R. Haselkorn,et al.  Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity , 2010, Proceedings of the National Academy of Sciences.

[24]  David A. Cheresh,et al.  Recent advances in cell adhesion molecules and extracellular matrix proteins: potential clinical implications , 1997 .

[25]  J. Boeke,et al.  Designer deletion strains derived from Saccharomyces cerevisiae S288C: A useful set of strains and plasmids for PCR‐mediated gene disruption and other applications , 1998, Yeast.

[26]  T. Geary,et al.  Haemonchus contortus: cloning and functional expression of a cDNA encoding ornithine decarboxylase and development of a screen for inhibitors. , 1997, Experimental parasitology.

[27]  Maria Liakata,et al.  Towards Robot Scientists for autonomous scientific discovery , 2010, Automated experimentation.

[28]  Sebastian Daum,et al.  The Trypanosoma cruzi PIN1 gene encodes a parvulin peptidyl-prolyl cis/trans isomerase able to replace the essential ESS1 in Saccharomyces cerevisiae. , 2007, Molecular and biochemical parasitology.

[29]  M. Zhang,et al.  Creation of a hyperpermeable yeast strain to genotoxic agents through combined inactivation of PDR and CWP genes. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  T. Geary,et al.  The changing landscape of antiparasitic drug discovery for veterinary medicine. , 2004, Trends in parasitology.

[31]  Robert P. St.Onge,et al.  The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes , 2008, Science.

[32]  Alex Loukas,et al.  A Novel High Throughput Assay for Anthelmintic Drug Screening and Resistance Diagnosis by Real-Time Monitoring of Parasite Motility , 2010, PLoS neglected tropical diseases.

[33]  Anton Simeonov,et al.  Identification of oxadiazoles as new drug leads for the control of schistosomiasis , 2008, Nature Medicine.

[34]  G. Franco,et al.  Schistosoma mansoni: Heterologous complementation of a yeast null mutant by SmRbx, a protein similar to a RING box protein involved in ubiquitination. , 2007, Experimental parasitology.

[35]  Túlio Marcos Santos,et al.  Functional complementation of a yeast knockout strain by Schistosoma mansoni Rho1 GTPase in the presence of caffeine, an agent that affects mutants defective in the protein kinase C signal transduction pathway. , 2006, Memorias do Instituto Oswaldo Cruz.

[36]  D. Botstein,et al.  A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds , 2009, Nature Biotechnology.

[37]  B. Haas,et al.  The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease , 2005, Science.

[38]  Ken E. Whelan,et al.  The Automation of Science , 2009, Science.

[39]  M. Pain,et al.  A Cell-Based High-Throughput Screen Validates the Plasmodial Surface Anion Channel As an Antimalarial Target , 2010, Molecular Pharmacology.

[40]  J. Lexchin.  One step forward, one step sideways? Expanding research capacity for neglected diseases , 2010, BMC international health and human rights.

[41]  R. Pink,et al.  Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.

[42]  Carol Hopkins Sibley,et al.  A database of antimalarial drug resistance , 2006, Malaria Journal.

[43]  Sean Ekins,et al.  When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? , 2010, Drug discovery today.

[44]  P. Selzer.  Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates , 2009 .

[45]  Christopher H. Bryant,et al.  Functional genomic hypothesis generation and experimentation by a robot scientist , 2004, Nature.

[46]  Mike Tyers,et al.  Off-Target Effects of Psychoactive Drugs Revealed by Genome-Wide Assays in Yeast , 2008, PLoS genetics.

[47]  E. Chatelain,et al.  Drug Discovery for Neglected Diseases: View of A Public–Private Partnership , 2009 .

[48]  Ian H. Gilbert,et al.  N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.

[49]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[50]  C. Carrillo,et al.  Trypanosoma cruzi amino acid transporter TcAAAP411 mediates arginine uptake in yeasts. , 2010, FEMS microbiology letters.

[51]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[52]  J. Beavo,et al.  Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents. , 2007, Molecular interventions.

[53]  J. Habbema,et al.  Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. , 2003, Acta tropica.

[54]  S. Audétat,et al.  Yeast as a screening tool. , 2005, Drug discovery today. Technologies.

[55]  E. Bilsland,et al.  Contributions of Saccharomyces cerevisiae to understanding mammalian gene function and therapy. , 2011, Methods in molecular biology.

[56]  Stephen G. Oliver,et al.  Yeast Systems Biology: Towards a Systems Understanding of Regulation of Eukaryotic Networks in Complex Diseases and Biotechnology , 2011 .

[57]  A. Serrano,et al.  N-terminal chimaeras with signal sequences enhance the functional expression and alter the subcellular localization of heterologous membrane-bound inorganic pyrophosphatases in yeast. , 2010, The Biochemical journal.

[58]  C. Naula,et al.  Protein kinases as drug targets in trypanosomes and Leishmania. , 2005, Biochimica et biophysica acta.

[59]  J. Maguire.  Chagas' disease--can we stop the deaths? , 2006, The New England journal of medicine.

[60]  S. Oliaro-Bosso,et al.  Oxidosqualene cyclase from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: a model for the development of novel antiparasitic agents. , 2009, Bioorganic & medicinal chemistry letters.

[61]  Frédéric Bringaud,et al.  Metabolic functions of glycosomes in trypanosomatids. , 2006, Biochimica et biophysica acta.

[62]  A. Gurvitz.  Identification of the Leishmania major Proteins LmjF07.0430, LmjF07.0440, and LmjF27.2440 as Components of Fatty Acid Synthase II , 2010, Journal of biomedicine & biotechnology.

[63]  Inmar E. Givoni,et al.  Exploring the Mode-of-Action of Bioactive Compounds by Chemical-Genetic Profiling in Yeast , 2006, Cell.

[64]  M Aldea,et al.  A Set of Vectors with a Tetracycline‐Regulatable Promoter System for Modulated Gene Expression in Saccharomyces cerevisiae , 1997, Yeast.

[65]  J. Phang,et al.  Identification of human intracellular targets of the medicinal Herb St. John's Wort by chemical-genetic profiling in yeast. , 2008, Journal of Agricultural and Food Chemistry.